- Home
- ABCL
as 07-26-2024 4:00pm EST
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company have extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.
| Founded: | 2012 | Country: | Canada |
| Employees: | N/A | City: | VANCOUVER |
| Market Cap: | 870.4M | IPO Year: | 2020 |
| Target Price: | $16.50 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.52 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.65 - $7.85 | Next Earning Date: | 08-06-2024 |
| Revenue: | $35,788,000 | Revenue Growth: | -80.23% |
| Revenue Growth (this year): | 11.3% | Revenue Growth (next year): | 26.84% |
Stock Insider Trading Activity of AbCellera Biologics Inc. (ABCL)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Montalbano John S. | ABCL | Director | Nov 6 '23 | Buy | $4.64 | 20,000 | $92,800.00 | 76,000 | SEC Form 4 |
| Montalbano John S. | ABCL | Director | Nov 6 '23 | Buy | $4.46 | 10,000 | $44,600.00 | 86,000 | SEC Form 4 |
Latest AbCellera Biologics Inc. News
ABCL Breaking Stock News: Dive into ABCL Ticker-Specific Updates for Smart Investing
Motley Fool
6 days ago
Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?
MT Newswires
15 days ago
--KeyBanc Adjusts Price Target on AbCellera Biologics to $5 From $7, Maintains Overweight Rating
Zacks
17 days ago
AbCellera Biologics (ABCL) Upgraded to Buy: Here's What You Should Know
Business Wire
a month ago
AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024
Motley Fool
a month ago
Down 57%, Is AbCellera Biologics a Buy on the Dip?
CNW Group
2 months ago
HEATHERWICK STUDIO UNVEILS ICONIC GLASS CANOPY, THE JEWEL IN THE CROWN OF REIMAGINED OLYMPIA
CNW Group
2 months ago
Hyundai Motor Presents Its First Film 'Night Fishing' in Collaboration with K-Movie Star Son Sukku
PR Newswire
2 months ago
IMAGO AIOS Prime Clinches Red Dot Award for 2024, Expands US Footprint with New Boston Warehouse
Compare ABCL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ABCL AbCellera Biologics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.